• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?

作者信息

Bomben Riccardo, Zucchetto Antonella, Pozzo Federico, Tissino Erika, Bittolo Tamara, Olivieri Jacopo, Chiarenza Annalisa, Zaja Francesco, Del Principe Maria Ilaria, Rossi Davide, Gattei Valter

机构信息

Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy.

Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi" DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy.

出版信息

Hemasphere. 2023 Apr 4;7(4):e855. doi: 10.1097/HS9.0000000000000855. eCollection 2023 Apr.

DOI:10.1097/HS9.0000000000000855
PMID:37034005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10079334/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfb2/10079334/7270aec6b560/hs9-7-e855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfb2/10079334/7270aec6b560/hs9-7-e855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfb2/10079334/7270aec6b560/hs9-7-e855-g001.jpg

相似文献

1
Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?慢性淋巴细胞白血病中的突变与临床结局：仍需要一个阈值吗？
Hemasphere. 2023 Apr 4;7(4):e855. doi: 10.1097/HS9.0000000000000855. eCollection 2023 Apr.
2
Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods.慢性淋巴细胞白血病患者体细胞TP53突变和17p缺失的检测：当前方法综述
Hematol Transfus Cell Ther. 2020 Jul-Sep;42(3):261-268. doi: 10.1016/j.htct.2020.05.005. Epub 2020 Jun 25.
3
Deep targeted sequencing of in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment.慢性淋巴细胞白血病中 的深度靶向测序：诊断时和治疗时的临床影响。
Haematologica. 2019 Apr;104(4):789-796. doi: 10.3324/haematol.2018.195818. Epub 2018 Dec 4.
4
aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.慢性淋巴细胞白血病的畸变：诊断改进的临床意义概述。
Haematologica. 2018 Dec;103(12):1956-1968. doi: 10.3324/haematol.2018.187583. Epub 2018 Nov 15.
5
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.新型 CHK1 抑制剂 MU380 在 TP53 突变的慢性淋巴细胞白血病细胞中表现出显著的单药活性。
Haematologica. 2019 Dec;104(12):2443-2455. doi: 10.3324/haematol.2018.203430. Epub 2019 Apr 11.
6
TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.临床实践中的TP53突变分析：来自慢性淋巴细胞白血病的经验教训
Hum Mutat. 2014 Jun;35(6):663-71. doi: 10.1002/humu.22508. Epub 2014 Feb 5.
7
Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.低变异等位基因频率的突变预示慢性淋巴细胞白血病患者生存期短。
Clin Cancer Res. 2021 Oct 15;27(20):5566-5575. doi: 10.1158/1078-0432.CCR-21-0701. Epub 2021 Jul 20.
8
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.TP53 基因突变状态作为慢性淋巴细胞白血病患者反应和生存的预测因子：LRF CLL4 试验的结果。
J Clin Oncol. 2011 Jun 1;29(16):2223-9. doi: 10.1200/JCO.2010.32.0838. Epub 2011 Apr 11.
9
Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.采用 AmpliChip p53 研究检测评估慢性淋巴细胞白血病中的 TP53 突变：与临床结果和基因表达谱的相关性。
Genes Chromosomes Cancer. 2011 Apr;50(4):263-74. doi: 10.1002/gcc.20852. Epub 2011 Jan 13.
10
Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.伴有 TP53 基因改变的慢性淋巴细胞白血病：一项详细的临床病理分析。
Mod Pathol. 2020 Mar;33(3):344-353. doi: 10.1038/s41379-019-0356-z. Epub 2019 Sep 2.

本文引用的文献

1
Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting.在临床环境中，5%的变异等位基因频率是慢性淋巴细胞白血病中通过下一代测序检测到的变异的可靠报告阈值。
Hemasphere. 2022 Aug 2;6(8):e761. doi: 10.1097/HS9.0000000000000761. eCollection 2022 Aug.
2
Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.低变异等位基因频率的突变预示慢性淋巴细胞白血病患者生存期短。
Clin Cancer Res. 2021 Oct 15;27(20):5566-5575. doi: 10.1158/1078-0432.CCR-21-0701. Epub 2021 Jul 20.
3
Clinical Outcomes in Patients with Multi-Hit Chronic Lymphocytic Leukemia Treated with Ibrutinib.
伊布替尼治疗多打击慢性淋巴细胞白血病患者的临床结局。
Clin Cancer Res. 2021 Aug 15;27(16):4531-4538. doi: 10.1158/1078-0432.CCR-20-4890. Epub 2021 May 7.
4
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.CLL 中低负担 TP53 突变：不同治疗选择背景下的临床影响和克隆进化。
Blood. 2021 Dec 23;138(25):2670-2685. doi: 10.1182/blood.2020009530.
5
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.4因素评分评估：对586例接受依鲁替尼治疗的慢性淋巴细胞白血病（CLL）患者的回顾性分析。一项校园CLL研究。
Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.
6
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.ERIC 推荐用于慢性淋巴细胞白血病 TP53 突变分析的方法——方法学方法和结果解释的更新。
Leukemia. 2018 May;32(5):1070-1080. doi: 10.1038/s41375-017-0007-7. Epub 2018 Feb 2.
7
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.慢性淋巴细胞白血病中克隆性和亚克隆性TP53、SF3B1、BIRC3、NOTCH1和ATM突变的临床影响
Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2.
8
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.慢性淋巴细胞白血病中小 TP53 突变亚克隆的临床影响。
Blood. 2014 Apr 3;123(14):2139-47. doi: 10.1182/blood-2013-11-539726. Epub 2014 Feb 5.